Barcelona-based venture capital firm Nina Capital has launched its third fund, securing €50 million to invest in early-stage healthtech startups. With Fund III, the firm aims to support innovative companies addressing critical challenges in healthcare through technology-driven solutions. The new fund expands Nina Capital's investment reach, now including Australia alongside its existing focus on Europe, North America, and Israel.

Expanding Geographic and Investment Scope

Nina Capital's latest fund will target companies operating at the intersection of healthcare and technology, spanning areas such as clinical innovation, healthcare infrastructure, and digital health solutions. The firm will back startups from pre-seed to Series A stages, deploying initial investments ranging from €250,000 to €1.5 million, with reserves for follow-on funding. By broadening its geographic scope, Nina Capital is positioning itself to capture emerging healthtech opportunities in new markets, particularly in Australia.

Backing Visionary Founders in Healthcare

The new fund has attracted investments from a diverse pool of contributors, including Boston-based wealth management firm Seven Two Partners, professional family offices, foundations, corporations, and high-net-worth individuals from Europe and the United States. Andrew Macken, Managing Partner at Seven Two, emphasized the importance of identifying and supporting visionary founders solving complex healthcare problems. He praised Nina Capital’s leadership, led by Marta-Gaia Zanchi, for its commitment to fostering groundbreaking innovations that drive both patient impact and investor returns.

First Investment and Future Plans

Nina Capital has already deployed its first Fund III investment in Sonar Mental Health, a U.S.-based platform combining AI and human-led support to assist students with mental health challenges. The firm plans to make two additional investments in early 2025, further solidifying its role as a key player in the healthtech sector. Fund III is expected to support 25 startups, with 60 percent of investments allocated to European companies and the remaining 40 percent primarily targeting U.S. and Australian ventures.

A Structured Approach to Healthcare Investment

Nina Capital follows a structured, need-driven approach to healthcare investment, applying the Stanford-developed Biodesign methodology to assess opportunities and mitigate risks. The firm focuses on companies leveraging engineering, data science, and IT-enabled healthcare solutions to drive systemic improvements. With this strategy, Nina Capital aims to not only provide financial backing but also offer industry expertise to help founders navigate the complex healthcare landscape.

Commitment to Long-Term Growth

Since its inception in 2019, Nina Capital has backed 50 companies across nearly 20 countries, impacting over 10 million lives through its portfolio. The firm typically acquires an 8 to 10 percent stake in its investments, with occasional higher ownership in select cases. Fundraising for Fund III commenced in September 2024, with the final close anticipated by the end of 2025, marking a continued commitment to shaping the future of healthtech innovation.

With the launch of Fund III, Nina Capital strengthens its position as a leading investor in early-stage healthtech startups, expanding its geographic footprint and investment capacity. By focusing on high-impact healthcare solutions and a rigorous investment approach, the firm is poised to drive meaningful advancements in patient care and industry transformation. As it continues to back pioneering healthtech ventures, Nina Capital reinforces its commitment to supporting founders who are reshaping the global healthcare landscape.